Adverum Bio (ADVM) Stock Forecast, Price Target & Predictions
ADVM Stock Forecast
Adverum Bio stock forecast is as follows: an average price target of $7.00 (represents a -3.18% downside from ADVM’s last price of $7.23) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ADVM Price Target
The average price target for Adverum Bio (ADVM) is $7.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $2.00. This represents a potential -3.18% downside from ADVM's last price of $7.23.
ADVM Analyst Ratings
According to 2 Wall Street analysts, Adverum Bio's rating consensus is 'Buy'. The analyst rating breakdown for ADVM stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Adverum Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Luca Issi | RBC Capital | $12.00 | $6.64 | 80.72% | 65.98% |
| Nov 11, 2022 | - | Chardan Capital | $2.00 | $0.71 | 183.65% | -72.34% |
The latest Adverum Bio stock forecast, released on Aug 13, 2024 by Luca Issi from RBC Capital, set a price target of $12.00, which represents a 80.72% increase from the stock price at the time of the forecast ($6.64), and a 65.98% increase from ADVM last price ($7.23).
Adverum Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $12.00 | $12.00 |
| Last Closing Price | $7.23 | $7.23 | $7.23 |
| Upside/Downside | -100.00% | 65.98% | 65.98% |
In the current month, the average price target of Adverum Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adverum Bio's last price of $7.23. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jun 25, 2024 | Oppenheimer | - | Outperform | Initialise |
| Nov 11, 2022 | RBC Capital | Sector Perform | Sector Perform | Hold |
Adverum Bio's last stock rating was published by RBC Capital on Aug 13, 2024. The company gave ADVM a "Sector Perform" rating, the same as its previous rate.
Adverum Bio Financial Forecast
Adverum Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $7.50M | - | - | - | - | - | $250.00K | - | - | $216.00K | $462.00K | $265.00K | $203.00K | $204.00K |
| Avg Forecast | - | - | - | - | $105.00K | $100.00K | $106.00K | $127.50K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $208.80K | $376.89K | $181.31K | $213.68K | $85.68K |
| High Forecast | - | - | - | - | $105.00K | $100.00K | $106.00K | $127.50K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $250.56K | $452.27K | $217.58K | $256.42K | $102.82K |
| Low Forecast | - | - | - | - | $105.00K | $100.00K | $106.00K | $127.50K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $167.04K | $301.51K | $145.05K | $170.95K | $68.54K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 81.52% | - | - | - | - | - | 0.94% | - | - | 1.03% | 1.23% | 1.46% | 0.95% | 2.38% |
Adverum Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $127.50K, with a low forecast of $127.50K, and a high forecast of $127.50K. ADVM's average Quarter revenue forecast represents a -98.30% decrease compared to the company's last Quarter revenue of $7.50M (Mar 21).
Adverum Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $-27.27M | $-36.55M | $-26.58M | $-27.90M | $-22.31M | $-20.19M | $-15.20M | $-13.99M | $-13.52M | $-16.74M | $-15.58M | $-15.07M | $-9.39M | $-8.21M |
| Avg Forecast | - | - | - | - | $-21.00K | $-20.00K | $-21.20K | $-25.50K | $-33.73M | $-15.33K | $-15.33K | $-15.33K | $-19.76M | $-50.67K | $-53.00K | $-75.50K | $-16.93M | $-16.16M | $-12.06M | $-8.93M | $-9.86M | $-3.44M |
| High Forecast | - | - | - | - | $-21.00K | $-20.00K | $-21.20K | $-25.50K | $-26.98M | $-15.33K | $-15.33K | $-15.33K | $-15.80M | $-50.67K | $-53.00K | $-75.50K | $-13.54M | $-12.93M | $-9.65M | $-7.14M | $-7.89M | $-2.75M |
| Low Forecast | - | - | - | - | $-21.00K | $-20.00K | $-21.20K | $-25.50K | $-40.47M | $-15.33K | $-15.33K | $-15.33K | $-23.71M | $-50.67K | $-53.00K | $-75.50K | $-20.31M | $-19.40M | $-14.48M | $-10.71M | $-11.83M | $-4.13M |
| Surprise % | - | - | - | - | - | - | - | - | 0.81% | 2384.07% | 1733.78% | 1819.80% | 1.13% | 398.51% | 286.85% | 185.37% | 0.80% | 1.04% | 1.29% | 1.69% | 0.95% | 2.39% |
undefined analysts predict ADVM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Adverum Bio's previous annual EBITDA (undefined) of $NaN.
Adverum Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $-28.44M | $-37.63M | $-27.77M | $-29.20M | $-22.91M | $-18.93M | $-16.12M | $-14.95M | $-14.49M | $-17.20M | $-16.10M | $-15.39M | $-9.51M | $-8.26M |
| Avg Forecast | $-25.02M | $-27.59M | $-30.58M | $-28.36M | $-29.09M | $-28.41M | $-30.60M | $-29.28M | $-35.17M | $-67.39M | $-71.59M | $-60.24M | $-19.51M | $-61.17M | $-55.26M | $-61.30M | $-16.64M | $-16.61M | $-12.46M | $-9.12M | $-9.98M | $-3.46M |
| High Forecast | $-25.02M | $-27.59M | $-30.58M | $-28.36M | $-29.09M | $-21.78M | $-30.60M | $-29.28M | $-28.14M | $-67.39M | $-71.59M | $-60.24M | $-15.61M | $-61.17M | $-55.26M | $-61.30M | $-13.31M | $-13.29M | $-9.97M | $-7.29M | $-7.99M | $-2.77M |
| Low Forecast | $-25.02M | $-27.59M | $-30.58M | $-28.36M | $-29.09M | $-31.73M | $-30.60M | $-29.28M | $-42.21M | $-67.39M | $-71.59M | $-60.24M | $-23.42M | $-61.17M | $-55.26M | $-61.30M | $-19.96M | $-19.93M | $-14.96M | $-10.94M | $-11.98M | $-4.15M |
| Surprise % | - | - | - | - | - | - | - | - | 0.81% | 0.56% | 0.39% | 0.48% | 1.17% | 0.31% | 0.29% | 0.24% | 0.87% | 1.04% | 1.29% | 1.69% | 0.95% | 2.39% |
Adverum Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADVM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Adverum Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $16.16M | $13.65M | $11.35M | $10.60M | $9.04M | $8.28M | $7.39M | $7.13M | $5.58M | $5.37M | $7.99M | $8.32M | $4.14M | $2.40M |
| Avg Forecast | - | - | - | - | $2.86M | $2.73M | $2.89M | $3.48M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $5.70M | $10.28M | $4.95M | $5.83M | $2.34M |
| High Forecast | - | - | - | - | $2.86M | $2.73M | $2.89M | $3.48M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $6.83M | $12.34M | $5.94M | $6.99M | $2.80M |
| Low Forecast | - | - | - | - | $2.86M | $2.73M | $2.89M | $3.48M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $4.56M | $8.22M | $3.96M | $4.66M | $1.87M |
| Surprise % | - | - | - | - | - | - | - | - | 6.44% | 6.53% | 5.43% | 5.07% | 3.05% | 1.20% | 1.02% | 0.69% | 0.64% | 0.94% | 0.78% | 1.68% | 0.71% | 1.03% |
Adverum Bio's average Quarter SG&A projection for Mar 24 is $3.48M, based on 1 Wall Street analysts, with a range of $3.48M to $3.48M. The forecast indicates a -78.48% fall compared to ADVM last annual SG&A of $16.16M (Mar 21).
Adverum Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| EPS | - | - | - | - | - | - | - | - | $-0.29 | $-0.38 | $-0.31 | $-0.36 | $-0.31 | $-0.26 | $-0.25 | $-0.23 | $-0.23 | $-0.30 | $-0.38 | $-0.57 | $-0.38 | $-0.37 |
| Avg Forecast | $-1.20 | $-1.32 | $-1.47 | $-1.36 | $-1.40 | $-1.36 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.28 | $-0.24 | $-0.23 | $-0.42 | $-0.09 |
| High Forecast | $-1.20 | $-1.32 | $-1.47 | $-1.36 | $-1.40 | $-1.04 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.22 | $-0.19 | $-0.18 | $-0.34 | $-0.07 |
| Low Forecast | $-1.20 | $-1.32 | $-1.47 | $-1.36 | $-1.40 | $-1.52 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.34 | $-0.29 | $-0.28 | $-0.50 | $-0.11 |
| Surprise % | - | - | - | - | - | - | - | - | 0.08% | 0.12% | 0.09% | 0.12% | 0.11% | 0.09% | 0.09% | 0.08% | 0.09% | 1.07% | 1.58% | 2.48% | 0.90% | 4.08% |
According to undefined Wall Street analysts, Adverum Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADVM previous annual EPS of $NaN (undefined).
Adverum Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| KZR | Kezar Life Sciences | $0.57 | $17.50 | 2970.18% | Buy |
| ONCT | Oncternal Therapeutics | $1.46 | $28.00 | 1817.81% | Buy |
| KOD | Kodiak Sciences | $2.71 | $32.80 | 1110.33% | Buy |
| QURE | uniQure | $5.66 | $53.67 | 848.23% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| RCKT | Rocket Pharmaceuticals | $19.65 | $47.33 | 140.87% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| SLDB | Solid Biosciences | $7.93 | $17.50 | 120.68% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| AFMD | Affimed | $4.00 | $7.50 | 87.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| ABSI | Absci | $3.90 | $6.00 | 53.85% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| GLMD | Galmed Pharmaceuticals | $4.11 | $5.00 | 21.65% | Buy |
| ADVM | Adverum Bio | $7.23 | $7.00 | -3.18% | Buy |
| RYTM | Rhythm Pharmaceuticals | $49.62 | $38.33 | -22.75% | Buy |
ADVM Forecast FAQ
Is Adverum Bio a good buy?
Yes, according to 2 Wall Street analysts, Adverum Bio (ADVM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of ADVM's total ratings.
What is ADVM's price target?
Adverum Bio (ADVM) average price target is $7 with a range of $2 to $12, implying a -3.18% from its last price of $7.23. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Adverum Bio stock go up soon?
According to Wall Street analysts' prediction for ADVM stock, the company can go down by -3.18% (from the last price of $7.23 to the average price target of $7), up by 65.98% based on the highest stock price target, and down by -72.34% based on the lowest stock price target.
Can Adverum Bio stock reach $11?
ADVM's highest twelve months analyst stock price target of $12 supports the claim that Adverum Bio can reach $11 in the near future.
What are Adverum Bio's analysts' financial forecasts?
Adverum Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $438.5K (high $438.5K, low $438.5K), average EBITDA is $-87.696K (high $-87.696K, low $-87.696K), average net income is $-117M (high $-111M, low $-121M), average SG&A $11.96M (high $11.96M, low $11.96M), and average EPS is $-5.629 (high $-5.311, low $-5.788). ADVM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-112M (high $-112M, low $-112M), average SG&A $0 (high $0, low $0), and average EPS is $-5.35 (high $-5.35, low $-5.35).
Did the ADVM's actual financial results beat the analysts' financial forecasts?
Based on Adverum Bio's last annual report (Dec 2019), the company's revenue was $250K, which missed the average analysts forecast of $1.22M by -79.44%. Apple's EBITDA was $-66.972M, beating the average prediction of $-17.105M by 291.53%. The company's net income was $-60.427M, missing the average estimation of $-194M by -68.91%. Apple's SG&A was $28.38M, missing the average forecast of $33.17M by -14.44%. Lastly, the company's EPS was $-0.94, missing the average prediction of $-11.203 by -91.61%. In terms of the last quarterly report (Mar 2021), Adverum Bio's revenue was $7.5M, beating the average analysts' forecast of $92K by 8052.17%. The company's EBITDA was $-27.27M, missing the average prediction of $-33.729M by -19.15%. Adverum Bio's net income was $-28.436M, missing the average estimation of $-35.171M by -19.15%. The company's SG&A was $16.16M, beating the average forecast of $2.51M by 544.04%. Lastly, the company's EPS was $-0.29, missing the average prediction of $-3.811 by -92.39%